Age-related macular degeneration

@article{Lim2012AgerelatedMD,
  title={Age-related macular degeneration},
  author={Laurence Shen Lim and Paul Mitchell and Johanna M. Seddon and Frank G. Holz and Tien Yin Wong},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={1728-1738}
}
Age-related macular degeneration is a major cause of blindness worldwide. With ageing populations in many countries, more than 20% might have the disorder. Advanced age-related macular degeneration, including neovascular age-related macular degeneration (wet) and geographic atrophy (late dry), is associated with substantial, progressive visual impairment. Major risk factors include cigarette smoking, nutritional factors, cardiovascular diseases, and genetic markers, including genes regulating… Expand
Age-related macular degeneration
TLDR
Progression from early-stage to late-stage disease can be slowed with high-dose zinc and antioxidant vitamin supplements, and future progress is likely to be from improved efforts in prevention and risk-factor modification, personalised medicine targeting specific pathways, newer anti-vascular endothelial growth factor agents or other agents, and regenerative therapies. Expand
Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy
TLDR
There is no approved treatment for geographic atrophy (GA), a debilitating late stage of dry AMD, and a large unmet need in this patient population, which is a leading cause of irreversible blindness in the elderly population in the Western Hemisphere. Expand
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration
TLDR
Assessment of the efficacy and safety of visual cycle modulators for the prevention and treatment of geographic atrophy secondary to AMD found emixustat may result in little or no difference in the annual growth rate of geographical atrophy compared with placebo. Expand
Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy
TLDR
Deep learning algorithm has been developed based on image recognition to distinguish wet AMD and normal macula with high accuracy and several new generation AMD drugs and iPSC-derived RPE cell therapy are in the clinical trial stage and are promising to improve AMD treatment in the near future. Expand
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
TLDR
The efficacy and safety of visual cycle modulators for the prevention and treatment of geographic atrophy secondary to AMD is assessed and emixustat may result in little or no difference in the annual growth rate of disease progression. Expand
Age-related macular degeneration (AMD): Current concepts in pathogenesis and prospects for treatment
TLDR
Stem cell therapy now holds great promise for various diseases, and AMD may well be one of the earliest diseases such treatment modality may be employed, considering the unique characteristics of the eye as a localized and immune-privileged organ. Expand
Relation between Fundus Autofluorescence and Optical Coherence Tomography in Age Related Macular Degeneration
TLDR
It was found from this study fifty eyes of thirty patients having AMD that the age ranged from 50 to75 years, FAF and OCT cannot replace FFA in cases of CNV, and FAF provides the opportunity to evaluate the retinal functional status. Expand
Introduction to the multi-author review on macular degeneration
  • A. Kauppinen
  • Medicine
  • Cellular and Molecular Life Sciences
  • 2020
TLDR
A bit broader look at age-related macular degeneration mechanisms at the cellular and molecular level is taken and in this multi-author review, some novel aspects are taken. Expand
Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration.
TLDR
There is markedly reduced RPE atrophy progression in areas co-localizing with quiescent and exudative type 1 CNV, compatible with a potential protective effect of type 2 CNV on the RPE and overlying neurosensory retina. Expand
Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
TLDR
Anti-VEGF treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime, a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Age-related macular degeneration – clinical review and genetics update
TLDR
This review addresses the potential of translating the wealth of genetic findings for improved risk prediction and therapeutic intervention in AMD patients and discusses the recent advancement in genetics and genomics. Expand
Genetic research provides insights into age-related macular degeneration.
TLDR
Experts are optimistic that this wealth of new information will spur additional discoveries that could ultimately delay or prevent AMD, making it one of the first major chronic diseases to benefit from pharmacogenetics and personalized medicine. Expand
Seven New Loci Associated with Age-Related Macular Degeneration
TLDR
A collaborative genome-wide association study, including >17,100 advanced AMD cases and >60,000 controls of European and Asian ancestry, identifies 19 loci associated at P < 5 × 10−8, which show enrichment for genes involved in the regulation of complement activity, lipid metabolism, extracellular matrix remodeling and angiogenesis. Expand
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
BACKGROUND Numerous population-based studies of age-related macular degeneration have been reported around the world, with the results of some studies suggesting racial or ethnic differences inExpand
Spare the rods, save the cones in aging and age-related maculopathy.
TLDR
The functional studies reviewed herein were facilitated by the development of standard fundus grading systems, which permit comparison of results from patients at similar stages of ARM across disciplines, and a better understanding of the mechanisms underlying normal human dark adaptation, which informs the interpretation of ageand diseaserelated changes. Expand
[Age-related macular degeneration].
  • A. Ramé
  • Medicine
  • Revue de l'infirmiere
  • 2006
TLDR
Age-related macular degeneration mainly affects central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces, and side vision and night vision are generally not affected. Expand
Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)
TLDR
A genome-wide association study of advanced age-related macular degeneration cases and controls using the Affymetrix 6.0 platform implicate different biologic pathways than previously reported and provide new avenues for prevention and treatment of AMD. Expand
Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration.
TLDR
The results suggest that a rapid DA test is useful for the detection of AMD and compared favorably to long-duration research methods for the measurement of DA, and slit lamp biomicroscopy performed by a retina specialist. Expand
Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration.
TLDR
Current findings on the genetics of AMD are discussed to highlight areas of rapid progress and new challenges and it is attempted to integrate available genetic and biochemical data with cellular pathways involved in aging to formulate an integrated model of AMD pathogenesis. Expand
Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration
TLDR
A genome-wide association scan for age-related macular degeneration (AMD) showed that 329 of 331 individuals with the highest-risk genotypes were cases, and 85% of these had advanced AMD, consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis. Expand
...
1
2
...